CD30+ T-cell lymphoproliferative disorders

Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders

It is critical to distinguish CD30+ T-cell LPDs from other CD30+ processes involving the skin that include: Systemic lymphomas (eg, systemic ALCL, ATLL, PTCL), Other cutaneous process such as other CD30+ skin lymphomas such as mycosis fungoides (MF), especially transformed MF, cytotoxic T-cell lymphomas, and Benign disorders such as lymphomatoid drug reactions, arthropod bites, viral infections...

CD30+ lymphoproliferative disorders.

27. Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, Wichmann F, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010;95(10):1668-74. 28. Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and M...

Presence of t(2;5) in primary CD30+ cutaneous lymphoproliferative disorders.

Single-Fraction Radiotherapy for CD30+ Lymphoproliferative Disorders

OBJECTIVES CD30(+) lymphoproliferative disorder is a rare variant of cutaneous T-cell lymphoma. Sustained complete response following first-line treatments is rare. This retrospective review evaluates the response of refractory or recurrent lesions to palliative radiation therapy. METHODS The records of 6 patients with 12 lesions, treated with radiation therapy, were reviewed. All patients re...

T cell and NK cell lymphoproliferative disorders.

This review covers the diagnosis and management of natural killer and peripheral T-cell lymphomas (PTCL). Problems with PTCL include their rarity, representing usually 10-15% of non-Hodgkin's lymphomas in the Western Hemisphere, morphologic heterogeneity, and lack of immunophenotypic markers for clonality. Additionally, their clinical behavior is variable and may not correlate with morphology. ...